{"id":"NCT00787254","sponsor":"Takeda","briefTitle":"Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs","officialTitle":"A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric and Duodenal Ulcers During Long-term Treatment With Nonsteroid Anti-inflammatory Drug","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04","primaryCompletion":"2009-05","completion":"2009-05","firstPosted":"2008-11-07","resultsPosted":"2011-05-10","lastUpdate":"2012-02-03"},"enrollment":366,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Stomach Ulcer","Duodenal Ulcer"],"interventions":[{"type":"DRUG","name":"Lansoprazole","otherNames":["AG-1749"]},{"type":"DRUG","name":"Gefarnate","otherNames":[]}],"arms":[{"label":"Lansoprazole 15 mg QD","type":"EXPERIMENTAL"},{"label":"Gefarnate 50 mg BID","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine whether AG-1749 (lansoprazole), once daily (QD), is effective in preventing the recurrence of gastric and duodenal ulcers in patients receiving long term treatment with nonsteroid anti-inflammatory drug, compared to gefarnate, twice daily (BID).","primaryOutcome":{"measure":"Number of Participants With Gastric Ulcer and/or Duodenal Ulcer","timeFrame":"24 Months","effectByArm":[{"arm":"Lansoprazole 15 mg QD","deltaMin":15,"sd":null},{"arm":"Gefarnate 50 mg BID","deltaMin":46,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":68,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":183},"commonTop":["Nasopharyngitis","Diarrhea","Fall","Constipation","Reflux esophagitis"]}}